BEIJING, April 15, 2025 /PRNewswire/ — Cheetah Mobile Inc. ("Cheetah Mobile" or the "Company") (NYSE: CMCM), a China-based IT company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission on April 15, 2025.

The annual report can be accessed on the Company’s investor relations website at http://ir.cmcm.com or the SEC’s website at www.sec.gov

About Cheetah Mobile Inc.

Cheetah Mobile is a China-based IT company with a commitment to AI innovation. It has attracted hundreds of millions of users through an array of internet products and services on PCs and mobile devices. At the same time, it actively engages in the independent research and development of AI technologies, including LLM technologies. Cheetah Mobile provides advertising services to advertisers worldwide, value-added services including the sale of premium membership to its users, multi-cloud management platform to companies globally, as well as service robots to international clients. Cheetah Mobile is also committed to leveraging its cutting-edge AI technologies, including LLM technologies, to empower its products and make the world smarter. It has been listed on the New York Stock Exchange since May 2014.

Investor Relations Contact

Helen Jing ZhuCheetah Mobile Inc.Tel: +86 10 6292 7779Email: ir@cmcm.com  

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Bedsure Expands into US Brick-and-Mortar Stores, Invites Partners to Join Pop-Up Showroom during NY Market Week

DIAMOND BAR, Calif., March 4, 2024 /PRNewswire/ — Renowned bedding brand Bedsure announces…

TCL Unveils Two New AI-Enhanced NXTPAPER Smartphones: Revolutionizing Smart Comfort for Consuming, Creating and Reading Content on the Go

BERLIN, Sept. 5, 2024 /PRNewswire/ — TCL, a pioneer in display across…

Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration

In the preliminary findings of a study conducted with the National Taiwan…